ArticleRadiation oncology (London, England)2014
Long-term results of radiotherapy in anaplastic thyroid cancer.
Article in Radiation oncology (London, England), 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 3 syntheses or guidelines pooled it, 43 citations in OpenAlex.
- Role of surgery to the primary tumor in metastatic anaplastic thyroid carcinoma: pooled analysis and SEER-based study.Journal of cancer research and clinical oncology · 2023Pooled it
- Efficacy and Safety of Lenvatinib in Anaplastic Thyroid Carcinoma: A Meta-Analysis.Frontiers in endocrinology · 2022Pooled it
- Anaplastic Thyroid Carcinoma, Version 2.2015.Journal of the National Comprehensive Cancer Network : JNCCN · 2015Guideline
- Prognostic factors in radiotherapy of anaplastic thyroid carcinoma: a single center study over 31 years.Radiation oncology (London, England) · 2023Trial
- Latin American Thyroid Society expert panel consensus on anaplastic thyroid cancer.Archives of endocrinology and metabolism · 2026Article
- Impact of Modern Systemic Therapies on Survival in Patients with Anaplastic Thyroid Cancer: A Single-Center Retrospective Cohort Review.Drugs - real world outcomes · 2025Article
- Article
- Anaplastic Thyroid Carcinoma: An Update.Cancers · 2022Review
- Primary squamous cell carcinoma of the thyroid: a case report.The Journal of international medical research · 2021Article
- Real-world experience of lenvatinib in patients with advanced anaplastic thyroid cancer.Endocrine · 2021Article
- Clinical Outcome and Toxicity in the Treatment of Anaplastic Thyroid Cancer in Elderly Patients.Journal of clinical medicine · 2020Article
- Review
- Expression of fibroblast growth factor receptor 4 and clinical response to lenvatinib in patients with anaplastic thyroid carcinoma: a pilot study.European journal of clinical pharmacology · 2020Article
- Article
- Combined Effect of Iodine Contrast Media, Cisplatin and External Beam Radiotherapy on Anaplastic Thyroid Cancer Cells.Journal of biomedical physics & engineering · 2019Article
- Hypofractionated Radiotherapy for Anaplastic Thyroid Carcinoma: 15 Years of Experience in a Single Institution.European thyroid journal · 2019Article
- An Update of the Appropriate Treatment Strategies in Anaplastic Thyroid Cancer: A Population-Based Study of 735 Patients.International journal of endocrinology · 2019Article
- Patterns of failure in anaplastic and differentiated thyroid carcinoma treated with intensity-modulated radiotherapy.Current oncology (Toronto, Ont.) · 2017Article
- Lenvatinib for Anaplastic Thyroid Cancer.Frontiers in oncology · 2017Article
- Short course high dose radiotherapy in the treatment of anaplastic thyroid carcinoma.Journal of thyroid research · 2014Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundAnaplastic thyroid cancer (ATC) is an aggressive malignant tumour with a poor prognosis. The median overall survival is described in the literature to be just 6 months, however, in series of selected patients treated by multimodal therapy cases of long-time-survival have been reported. We analyzed the role of radiotherapy and the impact of other therapies and clinical features on survival in patients with ATC.
methodsIn a retrospective analysis of all patients (n = 40), who presented with histologically proven ATC at a single centre between 1989 and 2008, patient and treatment characteristics with a focus on details of radiotherapy were registered and the survival status determined.
results39 of 40 patients received radiotherapy, 80% underwent surgery and 15% had chemotherapy. The median dosis of radiation was 50 Gy (6-60.4 Gy), in 87.5% fractionation was once daily. In 49.4% opposing-field techniques were applied, in 14% 3D-conformal-techniques and 32.5% combinations of both.The median overall survival (OS) was 5 months, 1-year survival 35.2% and 5-year-survival 21.6%. Interestingly, 24.3% survived 2 years or longer. Three factors could be identified as predictors of improved overall survival: absence of lymph node metastasis (N0) (median OS 18.3 months), median dose of radiation of 50 Gy or more (median OS 10.5 months) and the use of any surgery (median OS 10.5 months).
conclusionsDespite the generally poor outcome, the combination of surgery and intensive radiotherapy can result in long-term survival in selected patients with ATC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.